EUCTR2022-003788-13-FI进行中（未招募）1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both? - FAPStera
Heikki Minn0 个研究点目标入组 40 人开始时间: 2023年8月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Men with histologically confirmed prostate cancer. Age 50-85 years.
- •WHO performance score 0-2.
- •At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single-photon emission computed tomography (SPECT) imaging.
- •All previous treatment lines are allowed.
- •Patient signs informed consent form after receiving written information.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Patient is not able to understand the purpose of the study.
- •Medical conditions prohibiting whole-body PET/CT imaging.
研究者
相似试验
进行中（未招募）
1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Prostate cancerCTIS2024-511104-16-00Turku University Hospital40
已完成
1 期
Radionuclide therapy using Lutetium-177 prostate specific membrane antigen (PSMA): a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)Cancer - ProstateProstate CancerACTRN12615000912583Peter MacCallum Cancer Centre30
已完成
不适用
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)Prostate cancerNL-OMON42675Erasmus MC, Universitair Medisch Centrum Rotterdam525
已完成
不适用
Prostate Cancer Molecular Medicineprostate carcinoma1003859710036958Prostate cancerNL-OMON39774Erasmus MC, Universitair Medisch Centrum Rotterdam496
进行中（未招募）
1 期
Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50